Latest Breaking News On - France french national institute of health - Page 4 : comparemela.com
Quantum Genomics Announces the End of its Collaboration with Qilu for the Development and Commercialization of Firibastat in China
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Quantum Genomics Reports Full Year 2020 Operating and Financial Results
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Share:
PARIS and NEW YORK, Jan. 18, 2021 (GLOBE NEWSWIRE)
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure today announced the launch of its Phase III REFRESH study in difficult-to-treat
(
(2) hypertension.
This new study is part of firibastat s Phase III clinical development and aims to assess long-term safety as well as the three-month efficacy after a single daily dose of firibastat 1000mg in treatment resistant hypertensive patients. We are thrilled to launch this new pivotal study as a precursor to potential market approval of single dose firibastat, which we believe to be the best regimen for chronic treatment of resistant of difficult-to-treat hypertension, said Jean-Philippe Milon, Chief Executive Officer at Quantum Genomics.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Quantum Genomics Signs a Strategic Contract with Delpharm
Quantum GenomicsDecember 16, 2020 GMT
PARIS and NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat difficult-to-treat / resistant hypertension and heart failure, announces today that it has signed a strategic contract with Delpharm for the manufacture of the next clinical batches of firibastat tablets on an industrial scale and the establishment of production lines for future commercial batches.
vimarsana © 2020. All Rights Reserved.